MedTrace Logo

Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China

NCT01025544 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 846

Last updated 2011-12-08

No results posted yet for this study

Summary

This study will evaluate the safety and immunogenicity of booster doses of the two vaccines used to prevent Haemophilus influenzae type b infections in children 12-18 months of age.

Conditions

  • Haemophilus Influenzae Type b (Hib) Infection

Interventions

BIOLOGICAL

Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)

Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.

BIOLOGICAL

Hiberix (Haemophilus influenzae type b (Hib) vaccine)

Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.

Sponsors & Collaborators

  • Novartis Vaccines

    lead INDUSTRY

Principal Investigators

  • Novartis Basel · 41 61 324 1111

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
18 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2009-12-31
Completion
2010-04-30

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01025544 on ClinicalTrials.gov